NF-κB kinetics predetermine TNF-α sensitivity of colorectal cancer cells

Journal of Gene Medicine

Volumn 2, Issue 5, 2000, Pages 334-343

  Zwacka, Ralf M ^a   Stark, Lesley ^a   Dunlop, Malcolm G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Colorectal cancer; Gene therapy; NF B; TNF ; TRAIL

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; DNA BINDING PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CULTURE; COLORECTAL TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; KINETICS; METABOLISM;

ADENOVIRIDAE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DRUG RESISTANCE; GENE EXPRESSION; GENE THERAPY; HUMANS; I-KAPPA B PROTEINS; KINETICS; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034279755     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q     Document Type: Article

References (35)

1. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552-554.
2. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-729.
3. Sugarman BJ, Aggarwal BB, Mass PE, Figari IS, Palladino MAJ, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-945.
4. Hieber U, Heim ME. Tumor necrosis factor for the treatment of malignancies. Oncology 1994; 51: 142-153.
5. Morikawa K, Fidler IJ. Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1. J Biol Response Mod 1989; 8: 206-218.
6. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
7. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments]. Science 1996; 274: 782-784.
8. Wang CY, Mayo MW, Baldwin ASJ. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB [see comments]. Science 1996; 274: 784-787.
9. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998; 12: 2821-2830.
10. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-698.
11. Wong GH, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989; 58: 923-931.
12. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem 1996; 271: 18068-18073.
13. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin ASJ. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c- IAP1 and c- IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
14. Wang CY, Cusack JCJ, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-417.
15. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
16. Jeremias I, Debatin KM. TRAIL induces apoptosis and activation of NFkappaB. Eur Cytokine New 1998; 9: 687-688.
17. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999; 59: 6153-6158.
18. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563.
19. Aravind L, Dixit VM, Koonin EV. The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci 1999; 24: 47-53.
20. Baeuerle PA. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta 1991; 1072: 63-80.
21. Beg AA, Baldwin ASJ. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev 1993; 7: 2064-2070.
22. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB [see comments]. Nature 1997; 388: 548-554.
23. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF- kappaB activation [see comments]. Science 1997; 278: 860-866.
24. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997; 91: 243-252.
25. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am 1998; 12: 595-615.
26. Regenass U, Muller M, Curschellas E, Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemother-apeutic agents. Int J Cancer 1987; 39: 266-273.
27. Roff M, Thompson J, Rodriguez MS, et al. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 1996; 271: 7844-7850.
28. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of pro-inflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 1998; 160: 410-418.
29. Gilmore TD. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv 1992; 15: 69-87.
30. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999; 59: 811-815.
31. Lieber A, He CY, Meuse L, Himeda C, Wilson C, Kay MA. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol 1998; 72: 9267-9277.
32. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-2695.
33. Martin AG, Fresno M. TNF-α activation of NF-κB requires the phosphorylation of Ser 471 in the transactivation domain of c-Rel. J Biol Chem 2000 (epub ahead of print).
34. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 1998; 5: 1363-1371.
35. Blankenstein T, Qin ZH, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991; 173: 1047-1052.